吲哚布芬治疗冠心病合并低卒中风险非瓣膜性心房颤动患者的效果观察

Effect of indobufen on patients with coronary heart disease and non-valvular atrial fibrillation at low risk of stroke

目的探讨吲哚布芬在冠心病合并低卒中风险非瓣膜性心房颤动患者中的应用效果与安全性.方法40例冠心病合并低卒中风险非瓣膜性心房颤动患者,随机分为实验组和对照组,每组20例.实验组患者采用吲哚布芬进行抗血栓治疗,对照组患者采用阿司匹林进行抗血栓治疗.比较两组患者的脑卒中、心肌缺血无改善、总药物不良事件发生情况及血栓弹力图AA途径抑制率.结果治疗后,实验组患者的脑卒中、心肌缺血无改善、总药物不良事件发生率分别为5%、15%、5%,均明显低于对照组的30%、45%、30%,差异均具有统计学意义(P<0.05);两组患者的血栓弹力图AA途径抑制率比较,差异无统计学意义(P>0.05).结论吲哚布芬用于冠心病合并低卒中风险非瓣膜性心房颤动患者中的效果优于阿司匹林,不良反应更少,具有更好的临床安全性,值得推广应用.

Objective To discuss the effect and safety of indobufen on patients with coronary heart disease and non-valvular atrial fibrillation at low risk of stroke.Methods A total of 40 patients with coronary heart disease and non-valvular atrial fibrillation at low risk of stroke were randomly divided into experimental group and control group,with 20 cases in each group.The experimental group received indobufen for antithrombotic therapy,and the control group received aspirin for antithrombotic therapy.Comparison was made on occurrence of stroke,non-improvement in myocardial ischemia,total adverse drug events and inhibition rate of arachidonic acid(AA)pathway in thromboelastogram between the two groups.Results After treatment,the incidence of stroke,non-improvement in myocardial ischemia,total adverse drug events were 5%,15%and 5%in the experimental group,and those were obviously lower than 30%,45%and 30%in the control group.Their difference was statistically significant(P<0.05).There was no statistically significant difference in inhibition rate of AA pathway in thromboelastogram between the two groups(P>0.05).Conclusion Indobufen is superior to aspirin in the treatment of patients with coronary heart disease and non-valvular atrial fibrillation at low risk of stroke,with fewer adverse reactions and better clinical safety.It is worth popularizing and applying.